The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Clozapine-Induced Agranulocytosis After 11 Years of Treatment

To the Editor: Clozapine can cause life-threatening agranulocytosis in up to 0.8% of patients treated with this medication (1). This limits the use of clozapine and mandates regular hematological monitoring. The risk of blood dyscrasia is highest in the initial 6–18 weeks but has been reported after years of treatment (2). We present the case of a patient with schizophrenia who developed clozapine-induced agranulocytosis after 11 years of pharmacotherapy.

Mr. A, a 46-year-old Hispanic man, was diagnosed with chronic schizophrenia in the 1970s and had only partial response to various antipsychotic medications until clozapine was initiated 11 years ago. He improved significantly while taking clozapine, 675 mg/day. Recently, his psychosis worsened. At one of his routine biweekly hematological screenings, his WBC count was 1,300/mm3, his neutrophil count was 12%, and his bands were 2% (bands are immature neutrophils that increase when infection is present; normal ranges: WBC count=4,800–10,800/mm3, neutrophil count=42%–75%, and bands=0%–5%). That prompted a referral to the hospital. During the workup, a urinary tract infection was documented, despite an absence of clinical symptoms or signs of infection. In the previous 4 months, his WBC count had fluctuated between 2,800/mm3 to 5,000/mm3, with granulocyte counts in the normal range, and he had three periods documented when his WBC counts were below 4,000/mm3 (normal WBC count range=4,000–12,000/mm3). These leukopenias lasted 26, 22, and 5 days each and spontaneously resolved without changes in clozapine dosing.

Mr. A was hospitalized with neutropenic precautions, and clozapine was discontinued. Because of his mental status deterioration, aripiprazole, 15 mg/day, was started orally on day 4. Although his WBC count had risen to 1,600/mm3, one 480-mg dose of recombinant granulocyte colony stimulating factor was administered on the same day. On day 6, upper gastrointestinal bleeding occurred. An endoscopy revealed gastric ulcers that were cauterized. On day 10, a urinary tract infection was treated with trimethoprim-sulfamethoxazole. Mr. A’s WBC count gradually normalized to 5,300/mm3 (neutrophil count of 45.7%) on day 14 and remained normal throughout his hospitalization. He became more organized after 3 weeks of aripiprazole, 40 mg/day, but he did not regain his previous level of functioning. The risk for bone marrow suppression precluded restarting clozapine.

Clozapine can cause life-threatening agranulocytosis, which mandates weekly monitoring of the CBC during the first 6 months of treatment and biweekly monitoring thereafter. Neutropenia has been documented after 2.5 years of pharmacotherapy (2), and agranulocytosis has been reported after 17 months of treatment (3). In our patient, bone marrow suppression developed after 11 years of otherwise uncomplicated successful treatment with clozapine. Early detection of agranulocytosis reduces mortality (4). Although it involved a single case, this report suggests the importance of continued monitoring of CBC in clozapine-treated patients, even after many years of uncomplicated use.

References

1. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. N Engl J Med 1993; 329:162–167Crossref, MedlineGoogle Scholar

2. Bourin M, Guitton B, Dailly E, Hery P, Jolliet P: A follow-up study of a population of schizophrenic patients treated with clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:1481–1495Crossref, MedlineGoogle Scholar

3. Bhanji NH, Margolese HC, Chouinard G, Turnier L: Late-onset agranulocytosis in a patient with schizophrenia after 17 months of clozapine treatment. J Clin Psychopharmacol 2003; 23:522–523Crossref, MedlineGoogle Scholar

4. Atkin K, Kendall F, Gould D, Freeman H, Lieberman J, O’Sullivan D: The incidence of neutropenia and agranulocytosis in patients treated with clozapine in the UK and Ireland. Br J Psychiatry 1996; 169:483–488Crossref, MedlineGoogle Scholar